Skip to main content


Generic name: amivantamab-vmjw
Dosage form: injection, for intravenous use
Drug class: Miscellaneous antineoplastics

Medically reviewed by Judith Stewart, BPharm. Last updated on Sep 1, 2021.

What is Rybrevant?

Rybrevant is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that:

  • has spread to other parts of the body (metastatic) or cannot be removed by surgery, and
  • has a certain abnormal epidermal growth factor receptor “EGFR” gene(s) and
  • whose disease has worsened while on or after chemotherapy that contains platinum.

Your healthcare provider will perform a test to make sure that Rybrevant is right for you.
It is not known if this medicine is safe and effective in children.

Before you receive Rybrevant

Before you start treatment, tell your healthcare provider about all of your medical conditions, including if you:

  • have a history of lung or breathing problems
  • are pregnant or plan to become pregnant. Rybrevant can harm your unborn baby.
    Females who are able to become pregnant:
    • Your healthcare provider should do a pregnancy test before you start treatment.
    • You should use effective birth control (contraception) during treatment and for 3 months after your final dose.
    • Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment.
  • are breastfeeding or plan to breastfeed. It is not known if Rybrevant passes into your breast milk. Do not breastfeed during treatment and for 3 months after your final dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-thecounter medicines, vitamins, and herbal supplements.

How will I receive Rybrevant?

  • Rybrevant will be given to you by your healthcare provider by intravenous infusion into your vein.
  • Your healthcare provider will decide the time between doses as well as how many treatments you will receive.
  • Your healthcare provider will give you medicines before each dose to help reduce the risk of infusion-related reactions.
  • If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

What should I avoid while receiving Rybrevant?

Rybrevant can cause skin reactions. You should limit your time in the sun during and for 2 months after your treatment. Wear protective clothing and use sunscreen during treatment.

Rybrevant side effects

Serious side effects include:

  • infusion-related reactions. Infusion-related reactions are common with Rybrevant and can be severe or serious. Tell your healthcare provider right away if you get any of the following symptoms during your infusion:
    • shortness of breath
    • fever
    • chills
    • nausea
    • flushing
    • chest discomfort
    • lightheadedness
    • vomiting
  • lung problems. Rybrevant may cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you get any new or worsening lung symptoms, including shortness of breath, cough, or fever.
  • skin problems. Rybrevant may cause rash, itching, and dry skin. You may use alcohol-free moisturizing cream for dry skin. Tell your healthcare provider right away if you get any skin reactions. Your healthcare provider may treat you with a medicine(s) or send you to see a skin specialist (dermatologist) if you get skin reactions during treatment. See What should I avoid while receiving Rybrevant?
  • eye problems. Rybrevant may cause eye problems. Tell your healthcare provider right away if you get symptoms of eye problems which may include:
    • eye pain
    • dry eyes
    • eye redness
    • blurred vision
    • changes in vision
    • itchy eyes
    • excessive tearing
    • sensitivity to light

Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get eye problems during treatment. You should not use contact lenses until your eye symptoms are checked by a healthcare provider.

The most common side effects include:

  • rash
  • infusion-related reactions
  • infected skin around the nail
  • muscle and joint pain
  • shortness of breath
  • nausea
  • feeling very tired
  • swelling of hands, ankles, feet, face, or all of your body
  • sores in the mouth
  • cough
  • constipation
  • vomiting
  • changes in certain blood tests

Your healthcare provider may temporarily stop, decrease your dose or completely stop your treatment if you have serious side effects.
These are not all of the possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Rybrevant?

Other drugs may interact with amivantamab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

General information about safe and effective use of Rybrevant

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your healthcare provider or pharmacist for information that is written for health professionals.

What are the ingredients of Rybrevant?

Active ingredient: amivantamab-vmjw
Inactive ingredients: EDTA disodium salt dihydrate, L-histidine, L-histidine hydrochloride monohydrate, L-methionine, polysorbate 80, sucrose, and water for injection.

Popular FAQ

There are no head-to-head comparative studies of Exkivity to Rybrevant, so it is not possible to say if one is better than the other. In clinical studies, both treatments led to responses in some patients: Close to 28% of patients had a partial response (tumor shrinkage) to Exkivity treatment and the response lasted for about 17.5 months. About 40% of participants had a response to Rybrevant treatment, and the duration of response (DoR) lasted for a median of 11.5 months. Continue reading

Rybrevant works by targeting the epidermal growth factor receptor (EGFR) exon 20 insertion mutation and MET found in adult patients with certain types of non-small cell lung cancer (NSCLC). EGFR and MET are proteins that helps cells to grow. Targeting these proteins helps to slow down cancer growth. Continue reading

Rybrevant is given as an intravenous (IV) infusion into your vein weekly for four weeks, then it is given every two weeks. Your first dose will be split into two infusions given on two consecutive days. Your healthcare provider will administer this medication. Continue reading

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.